Tag Archives: PTC Therapeutics Inc.

PTC THERAPEUTICS TO PRESENT AT THE NORTH AMERICAN CYSTIC FIBROSIS CONFERENCE

SOUTH PLAINFIELD, NJ – October 10, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that the following two posters will be presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah, on October 17-19: – The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in […]

Continue Reading

PTC Therapeutics Expands Management Team

South Plainfield, NJ – October 1, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Mr. Martin Rexroad as Senior Vice President, Human Resources and Mr. R.A. Session II as Vice President, Corporate Development, both reporting to Ms. Cláudia Hirawat, President of PTC Therapeutics, Inc. In addition, Dr. Jay Barth has been […]

Continue Reading

PTC Therapeutics Announces Achievement of Major Milestone in SMA Collaboration

PTC to Receive $10 Million Payment from Roche – SOUTH PLAINFIELD, NJ – August 8, 2013 – PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the selection of a development candidate in its spinal muscular atrophy (SMA) collaboration with Roche and the SMA Foundation. The achievement of the milestone triggers a $10 million payment to PTC from […]

Continue Reading

PTC THERAPEUTICS APPOINTS SHANE KOVACS AS CHIEF FINANCIAL OFFICER

SOUTH PLAINFIELD, NJ – June 3, 2013 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Shane Kovacs as Chief Financial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr. Kovacs will be responsible for all finance-related activities at PTC   Continue Reading

Continue Reading

PTC Therapeutics Closes $60 Million Private Financing

March 7, 2013 Funds to support Phase 3 confirmatory trials of ataluren- SOUTH PLAINFIELD, NJ – March 7, 2013 – PTC Therapeutics, Inc. (PTC) today announced the successful completion of a $60 million financing led by Brookside Capital Partners Fund, L.P. Joining Brookside as new investors in this financing are Adage Capital Management, Jennison Associates […]

Continue Reading

PTC Recognizes Rare Disease Day by Launching Living with a Rare Disorder Site

In honor of Rare Disease Day, we are proud to introduce our Living with a Rare Disorder site. The site currently includes stories of patients living with Duchenne muscular dystrophy, cystic fibrosis and spinal muscular atrophy. Through these stories, which are told by the patients’ mothers, we hope to raise awareness about rare disorders. Click […]

Continue Reading

PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy

    Dear Friends, As announced this morning, PTC is very pleased to have received the acceptance for review of our application for conditional approval in the EU. This is a historic moment for the Duchenne muscular dystrophy community and for PTC, as this is the first filing of a marketing authorization application for a […]

Continue Reading

PTC THERAPEUTICS RECEIVES $1 MILLION GRANT AWARD FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) TO SUPPORT RESEARCH FOR A TREATMENT FOR DENGUE FEVER

SOUTH PLAINFIELD, NJ – October 22, 2012 – PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to discover antiviral agents for the treatment of dengue fever, a mosquito-borne disease that is a […]

Continue Reading

PTC THERAPEUTICS CLOSES $30 MILLION FINANCING

SOUTH PLAINFIELD, NJ – July 23, 2012 – PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S, and other existing investors. Read More

Continue Reading

PTC THERAPEUTICS ANNOUNCES ACHIEVEMENT OF MAJOR MILESTONE IN WELLCOME TRUST BMI1 COLLABORATION

SOUTH PLAINFIELD, NJ – July 11, 2012 – PTC Therapeutics, Inc. (PTC) today announced that it has selected an experimental drug candidate to advance in its BMI1 program for aggressive and drug-resistant tumors. The milestone triggers drawdown of the next $2.3 million installment of its Seeding Drug Discovery Award from the Wellcome Trust. Read more

Continue Reading
Follow

Get every new post delivered to your Inbox.

Join 85 other followers